4//SEC Filing
OrbiMed Israel GP Ltd. 4
Accession 0001551986-20-000295
CIK 0001551986other
Filed
Nov 2, 7:00 PM ET
Accepted
Nov 3, 4:14 PM ET
Size
8.9 KB
Accession
0001551986-20-000295
Insider Transaction Report
Form 4
OrbiMed Israel GP Ltd.
Director10% Owner
Transactions
- Other
Common stock
2020-10-30+1,943,734→ 25,716,755 total(indirect: see footnote)
OrbiMed Israel BioFund GP Limited Partnership
Director10% Owner
Transactions
- Other
Common stock
2020-10-30+1,943,734→ 25,716,755 total(indirect: see footnote)
Footnotes (3)
- [F1]The shares of common stock of the Issuer reported on this Form 4 were released from escrow pursuant to Section 1.12 of that certain Agreement and Plan of Merger and Reorganization dated as of October 6, 2019 (as amended by Amendment No. 1 thereto, dated as of December 17, 2019). The Reporting Person's right to receive such escrowed shares became fixed and irrevocable on October 30, 2020, the six-month anniversary of the closing date of the merger.
- [F2]These securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP.
- [F3]This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Nissim Darvish, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.
Documents
Issuer
9 METERS BIOPHARMA, INC.
CIK 0001551986
Entity typeother
IncorporatedIsrael
Related Parties
1- filerCIK 0001569590
Filing Metadata
- Form type
- 4
- Filed
- Nov 2, 7:00 PM ET
- Accepted
- Nov 3, 4:14 PM ET
- Size
- 8.9 KB